Novo Nordisk's patent on semaglutide expires this week in India, triggering an expected wave of lower-cost generics from local drugmakers. The shift should put downward pressure on semaglutide pricing and branded market share while expanding access, but raises concerns about uneven regulatory oversight and risks in an overcrowded market.
Novo Nordisk's patent on semaglutide expires this week in India, triggering an expected wave of lower-cost generics from local drugmakers. The shift should put downward pressure on semaglutide pricing and branded market share while expanding access, but raises concerns about uneven regulatory oversight and risks in an overcrowded market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
